4SC AG Further Strengthens Supervisory Board
Complete the form below to unlock access to ALL audio articles.
4SC AG has announced the appointment of Dr Irina Antonijevic and Mr Klaus Kühn to the company's Supervisory Board.
In a by-election at Annual General Meeting of 4SC AG, Dr Antonijevic and Mr Kühn were elected to the Supervisory Board for the remaining term of Dr Jörg Neermann and Mr Günter Frankenne, who have stepped down from the Supervisory Board.
The terms of office will run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for financial year 2012.
Dr Antonijevic, Director Clinical Research at US pharmaceutical company Sanofi, has many years of international experience in clinical drug development and extensive expertise gained in executive positions both in the pharmaceutical industry and in medical research in a university environment.
Klaus Kühn, former Chief Financial Officer of Bayer AG (2002 to 2010), has more than 30 years of experience in executive positions primarily in the chemical and pharmaceutical industry with a focus on finance and accounting.
The shareholders of 4SC AG also approved all of the resolutions proposed to the Annual General Meeting by the Management Board and the Supervisory Board with the required majority, including the following items:
• Resolution on the approval of the remuneration system for members of the Management Board;
• Approval of a control and profit transfer agreement between 4SC AG and 4SC Discovery GmbH;
• Resolution on the creation of new Authorized Capital, adjusted to the share capital that was raised following the capital increase in June 2012;
• Resolution on a new authorization of the Management Board to issue convertible bonds, bonds with warrants, profit participation rights and/or income debentures and create corresponding Conditional Capital.
A total of 78.3% of the voting capital was represented at the 2012 Annual General Meeting of 4SC AG.
